Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413582 | 0.88 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL29220644 | 0.82 | LMNA (0.38) | ALDH1A1LMNASMN1; SMN2KDM4ETSHR | |
| SCHEMBL16406009 | 0.81 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL15452989 | 0.81 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL14142658 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNASMN1; SMN2METKDM4E | |
| SCHEMBL465539 | 0.81 | HPGD (0.69) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL28324720 | 0.79 | CDK1 (0.48) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL663469 | 0.79 | MAOA (0.44) | ALDH1A1LMNAHPGDSMN1; SMN2FDPS | |
| SCHEMBL3022393 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL4860318 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038781-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS OR CHRONIC HEART FAILURE | LUCY THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| CN-102695546-B | Heterocylcic derivatives as inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2014-09-10 | — | — | CN | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| CN-102695546-A | Heterocylcic derivatives as inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2012-09-26 | — | — | CN | disclosed |
| EP-2475428-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2011029920-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2011-03-17 | — | — | WO | disclosed |
| EP-1455785-B1 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THE USE OF THE SAME | BAYER HEALTHCARE AG (DE) | 2009-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ALDH1A1 2195/4885LMNA 3569/4885MAPT 4151/4885 |
| US-20160039795-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ALDH1A1 2195/4885LMNA 3569/4885MAPT 4151/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ALDH1A1 2195/4885LMNA 3569/4885MAPT 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.